Custom-Made vaccine trains immune system to attack tumors

NCT ID NCT07002203

Recruiting now Disease control Sponsor: Seqker Biosciences, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 16 times

Summary

This study tests a personalized vaccine made from a patient's own tumor mutations. It aims to help the immune system recognize and attack cancer. Ten adults with advanced or high-risk solid tumors will receive the vaccine along with immune-boosting drugs. The goal is to see if the treatment is safe and helps control the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Horizon Cancer Excellence Center, Bumrungrad International Hospital
RECRUITING

Bangkok, 10110, Thailand

Contact Phone: •••-•••-•••• Email: •••••@•••••
Phyathai-1 Hospital
RECRUITING

Bangkok, 10400, Thailand

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ADVANCED CANCER NEOANTIGEN-SPECIFIC IMMUNOTHERAPY PERSONALIZED CANCER VACCINE RECURRENT CANCER RECURRENT CANCER SOLID TUMORS SOLID TUMORS